Glaukos Future Growth

Future criteria checks 1/6

Glaukos se prevé un crecimiento anual de los beneficios y los ingresos de 38.7% y 14.8% respectivamente. Se prevé que el BPA sea de grow en 37.8% al año. Se prevé que la rentabilidad de los fondos propios sea de -19.8% en 3 años.

Key information

47.3%

Earnings growth rate

45.6%

EPS growth rate

Medical Equipment earnings growth	16.1%
Revenue growth rate	17.9%
Future return on equity	1.2%
Analyst coverage	Good
Last updated	26 Mar 2024

Recent future growth updates

Recent updates

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Feb 21

Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Apr 19

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Feb 19

Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through

Feb 14

Glaukos sees positive data from mid-stage trial of dry eye treatment

Jan 10

Glaukos: Show Me The Money

Nov 10

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Oct 16

Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80

Aug 24

Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision

Aug 04

Glaukos gains as Stifel upgrades to Buy citing 2022 sales upside

Jul 12

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Mar 14

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Nov 29

Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

Aug 15

Earnings and Revenue Growth Forecasts

NYSE:GKOS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	574	-45	-21	193	8
12/31/2025	445	-74	-72	38	14
12/31/2024	357	-113	-39	-19	14
12/31/2023	315	-135	-78	-58	N/A
9/30/2023	304	-129	-75	-51	N/A
6/30/2023	297	-126	-97	-70	N/A
3/31/2023	289	-139	-104	-74	N/A
12/31/2022	283	-99	-63	-33	N/A
9/30/2022	285	-90	-65	-34	N/A
6/30/2022	288	-56	-25	11	N/A
3/31/2022	294	-28	-7	30	N/A
12/31/2021	294	-50	-23	25	N/A
9/30/2021	294	-38	-1	40	N/A
6/30/2021	284	-60	-19	13	N/A
3/31/2021	238	-83	-29	-6	N/A
12/31/2020	225	-120	-30	-23	N/A
9/30/2020	218	-73	-44	-38	N/A
6/30/2020	211	-71	-37	-31	N/A
3/31/2020	238	-37	-19	-14	N/A
12/31/2019	237	15	-5	0	N/A
9/30/2019	225	-19	10	21	N/A
6/30/2019	211	-12	17	28	N/A
3/31/2019	195	-12	16	26	N/A
12/31/2018	181	-13	9	19	N/A
9/30/2018	169	-14	10	14	N/A
6/30/2018	165	-6	11	17	N/A
3/31/2018	163	-4	11	17	N/A
12/31/2017	159	0	20	26	N/A
9/30/2017	151	-1	N/A	17	N/A
6/30/2017	140	-1	N/A	14	N/A
3/31/2017	127	5	N/A	16	N/A
12/31/2016	114	5	N/A	12	N/A
9/30/2016	102	2	N/A	8	N/A
6/30/2016	91	-1	N/A	4	N/A
3/31/2016	80	-35	N/A	-2	N/A
12/31/2015	72	-37	N/A	-2	N/A
9/30/2015	66	-40	N/A	-3	N/A
6/30/2015	59	-39	N/A	-2	N/A
3/31/2015	52	-9	N/A	-3	N/A
12/31/2014	46	-12	N/A	-7	N/A
9/30/2014	38	-11	N/A	-8	N/A
6/30/2014	33	-12	N/A	-10	N/A
3/31/2014	26	-13	N/A	-13	N/A
12/31/2013	21	-13	N/A	-13	N/A

Analyst Future Growth Forecasts

Ingresos vs. tasa de ahorro: GKOS se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios frente mercado: GKOS se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: GKOS se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: GKOSSe prevé que los ingresos de la empresa (14.8% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: GKOSSe prevé que los ingresos de la empresa (14.8% al año) crezcan más despacio que 20% al año.

Earnings per Share Growth Forecasts

Future Return on Equity

Futura rentabilidad financiera (ROE): GKOSSe prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (9.5%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Glaukos Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Glaukos Corporation Reaffirms Financial Guidance for 2024

Forecast to breakeven in 2026

Glaukos Corporation Announces Preliminary and Unaudited Net Sales for the Fourth Quarter and Full Year of 2023; Reaffirms Net Sales Guidance for the Year 2024

Forecast to breakeven in 2026

Glaukos Corporation Re-Affirms Revenue Guidance for the Year 2023 and 2024

Glaukos Corporation Revises Consolidated Revenue Guidance for the Year 2023

Recent updates

Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

New minor risk - Insider selling

President & COO recently sold US$2.0m worth of stock

President & COO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Glaukos Corporation Reaffirms Financial Guidance for 2024

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Forecast to breakeven in 2026

President & COO notifies of intention to sell stock

Glaukos Corporation to Report Q4, 2023 Results on Feb 21, 2024

President & COO notifies of intention to sell stock

New minor risk - Profitability

Is Glaukos (NYSE:GKOS) A Risky Investment?

Glaukos Corporation Announces Preliminary and Unaudited Net Sales for the Fourth Quarter and Full Year of 2023; Reaffirms Net Sales Guidance for the Year 2024

Glaukos: Remains A Hold Due To High Valuation And Negative Profitability

Chairman & CEO notifies of intention to sell stock

Forecast to breakeven in 2026

Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Chairman & CEO notifies of intention to sell stock

Glaukos Corporation Re-Affirms Revenue Guidance for the Year 2023 and 2024

Glaukos Corporation Revises Consolidated Revenue Guidance for the Year 2023

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Glaukos Corporation to Report Q3, 2023 Results on Nov 01, 2023

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Chairman & CEO notifies of intention to sell stock

Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support

Independent Director notifies of intention to sell stock

Glaukos Corporation Revises Sales Guidance for the Year 2023

New minor risk - Shareholder dilution

Price target increased by 9.5% to US$81.56

Price target increased by 13% to US$72.30

Glaukos Corporation to Report Q2, 2023 Results on Aug 02, 2023

Chairman & CEO notifies of intention to sell stock

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Glaukos: Revising To Buy On These 3 Catalytic Factors

Price target increased by 9.2% to US$62.90

Chairman & CEO notifies of intention to sell stock

Glaukos Corporation Announces the Completion of Enrollment and Randomization in Its Second Phase 3 Confirmatory Pivotal Trial for Epioxa

Chairman & CEO notifies of intention to sell stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Glaukos Corporation Revises Sales Guidance for the Year 2023

Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Insufficient new directors

Independent Director exercised options to buy US$480k worth of stock.

Consensus EPS estimates fall by 21%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through

Glaukos Corporation to Report Q4, 2022 Results on Feb 22, 2023

Glaukos Corporation Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability

Glaukos Corporation Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

Glaukos sees positive data from mid-stage trial of dry eye treatment

Glaukos: Show Me The Money

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Glaukos Corporation Provides Revenue Guidance for the Year 2022

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Glaukos Corporation to Report Q3, 2022 Results on Nov 02, 2022

Glaukos Corporation Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles

Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80

Consensus forecasts updated

Price target increased to US$59.00

Glaukos Corporation Revises Sales Guidance for the Year 2022

Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision

Glaukos Corporation to Report Q2, 2022 Results on Aug 03, 2022

Glaukos gains as Stifel upgrades to Buy citing 2022 sales upside

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?